Clinical Trial Update: Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating obinutuzumab with ibrutinib in relapsed/refractory mantle cell lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-01-05